Mylan Settles Charges With SEC
Regulators said the pharmaceutical company failed to make disclosures around the DOJ’s investigation of its EpiPen.
CFOs on the Move: Week Ending August 2
REGO Restaurant Group, Scena Retail Group, General Electric, Mylan, Brighthouse Financial, Maxim Integrated Products, Valencell, New York Power Authority
Pfizer and Mylan to Combine Off-Patent Drugs Businesses
The combined company, which will sell Mylan’s EpiPen and Pfizer’s Viagra, could draw annual sales of more than $20 billion.
Mylan Underpaid U.S. on Rebates for EpiPen
A federal official says the drugmaker misclassified EpiPen, possibly costing Medicaid millions of dollars in rebates.
Teva to Buy Allergan’s Generic Drug Unit for $40.5B
If the deal is approved, Teva says the combined company would have revenue of about $26 billion and EBITDA of $9.5 billion in 2016.